Baidu
map

雅培紧急召回Ellipse除颤器,其中31个设备已在患者体内

2019-08-20 除颤器 除颤器

8月初,FDA发布公告称,雅培正在召回Ellipse 植入式心律转复除颤器(ICD),因暴露的铝线可能会影响除颤治疗。FDA已将此视为一级召回,这是最严重的召回类型,因为设备可能导致严重伤害或死亡。雅培植入式心律转复除颤器通能够植入上胸部区域的皮肤下,通过绝缘线连接心脏监测信号。如果心跳过慢(心动过缓)、过快(心动过速)或需要协调治疗心力衰竭,患者就可能需要植入式心脏装置。雅培表示,由于制造工艺错

8月初,FDA发布公告称,雅培正在召回Ellipse 植入式心律转复除颤器(ICD),因暴露的铝线可能会影响除颤治疗。FDA已将此视为一级召回,这是最严重的召回类型,因为设备可能导致严重伤害或死亡。

雅培植入式心律转复除颤器通能够植入上胸部区域的皮肤下,通过绝缘线连接心脏监测信号。如果心跳过慢(心动过缓)、过快(心动过速)或需要协调治疗心力衰竭,患者就可能需要植入式心脏装置。

雅培表示,由于制造工艺错误导致部分铝线暴露,未完全绝缘的铝线容易导致电容器的短路,潜在的影响可能使得设备无法正常使用,且目前没有可行的方法或程序来确定哪些设备在发生故障之前存在此问题。

6月21日,雅培向客户发送了一份紧急医疗设备召回函,指示客户检查设备型号和序列号以识别受影响的患者并将确认表返回给销售代表,并建议进行设备分离和更换,雅培将提供替换设备。

据FDA公告,雅培在美国召回的设备共有108件,批次为 2019年4月5日至5月29日期间生产的所有批次,型号为:CD1377-36C,CD1377-36QC,CD1411-36Q,CD2377-36QC,CD2411-36C,CD2411-36Q,其中 31 件已经植入患者体内,目前这 31 件设备尚无患者受伤和死亡的报告。

参考资料:

Abbott (Formerly St. Jude Medical Inc.), Recalls Ellipse Implantable Cardioverter Defibrillators Due to Exposed Aluminum Wires That May Prevent Defibrillation Therapy

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1377778, encodeId=7c5913e777812, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439163, encodeId=07f7143916355, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489273, encodeId=365914892e3b0, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523265, encodeId=faec1523265ce, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579917, encodeId=b8ce15e99176b, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2019-08-22 chengjn
  2. [GetPortalCommentsPageByObjectIdResponse(id=1377778, encodeId=7c5913e777812, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439163, encodeId=07f7143916355, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489273, encodeId=365914892e3b0, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523265, encodeId=faec1523265ce, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579917, encodeId=b8ce15e99176b, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
    2019-08-22 zhouqu_8
  3. [GetPortalCommentsPageByObjectIdResponse(id=1377778, encodeId=7c5913e777812, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439163, encodeId=07f7143916355, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489273, encodeId=365914892e3b0, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523265, encodeId=faec1523265ce, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579917, encodeId=b8ce15e99176b, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1377778, encodeId=7c5913e777812, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439163, encodeId=07f7143916355, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489273, encodeId=365914892e3b0, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523265, encodeId=faec1523265ce, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579917, encodeId=b8ce15e99176b, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1377778, encodeId=7c5913e777812, content=<a href='/topic/show?id=17b810004ce' target=_blank style='color:#2F92EE;'>#iPS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10004, encryptionId=17b810004ce, topicName=iPS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=69cb413, createdName=chengjn, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1439163, encodeId=07f7143916355, content=<a href='/topic/show?id=8e3a98396f2' target=_blank style='color:#2F92EE;'>#除颤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=53, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98396, encryptionId=8e3a98396f2, topicName=除颤)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1489273, encodeId=365914892e3b0, content=<a href='/topic/show?id=fde43840491' target=_blank style='color:#2F92EE;'>#召回#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=59, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=38404, encryptionId=fde43840491, topicName=召回)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1df18514500, createdName=doctorzheng, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1523265, encodeId=faec1523265ce, content=<a href='/topic/show?id=1a1de7006b0' target=_blank style='color:#2F92EE;'>#紧急#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=77006, encryptionId=1a1de7006b0, topicName=紧急)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b88211514540, createdName=guguangxiang, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1579917, encodeId=b8ce15e99176b, content=<a href='/topic/show?id=0ebc98e077a' target=_blank style='color:#2F92EE;'>#雅培#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98707, encryptionId=0ebc98e077a, topicName=雅培)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80e616567008, createdName=12498877m103暂无昵称, createdTime=Thu Aug 22 01:22:00 CST 2019, time=2019-08-22, status=1, ipAttribution=)]

相关资讯

JACC:经皮除颤器植入的安全性和疗效性研究

经皮电复律除颤器的植入(S-ICD)是用来治疗室性心律失常的技术,S-ICD临床结果和成本效益因素评价(EFFORTLESS S-ICD)的数据库记录了985名患者5年的随访预后情况。近日,在国际心血管权威杂志JACC上发表了一篇旨在通过EFFORTLESS S-ICD数据库评估分析S-ICD的安全性和不良休克发生率的临床研究。本研究的主要终点事件是术后30天和360天的并发症,心房颤动或室上性心

NEJM:心脏起搏器或除颤器植入患者接受MRI检查是安全的

研究认为,对于植入传统起搏器或除颤器的患者,磁共振检查是安全的,未发生长期临床显著性不良事件

Nat Commun:虚拟心脏能减少心脏病发病

本周《自然—通讯》上发表的一项研究显示,遭受了心脏病的患者可以通过心脏的个性化电脑模型评估下一次出现心律失常的风险。心律失常是一种可以危及生命的心脏不规则跳动。这些3D电脑模型可以识别高风险的病人,从而让这些病人意识到自己可能需要做手术植入心脏除颤器。 尽管心律失常导致的心源性猝死是发达国家首要的死亡原因之一,现有的识别高风险患者的方法没有考虑到患者心脏几何形状的具体差异,从而治疗效果有限。

FDA批准一款MRI兼容心衰设备,允许携带起搏器检测

日前,美敦力公司旗下MRI兼容的心脏节律和心力衰竭设备获得FDA批准,该设备允许身体任何部位带有起搏器或植入式除颤器设备的患者,可直接进行MRI扫描。美敦力公司在一份声明中表示,每年约12%至16%体内有心脏装置的患者需要进行MRI检查,但是由于MRI可能会对起搏器造成相应的影响,因此实际上仅有小于1%的患者接受过MRI成像检查。声明中提到,得益于FDA对该项设备的批准,体内含有Medtronic

NEJM:VEST研究发表:可穿戴式除颤器未发挥保护作用?穿戴时间不够或是原因之一

近年来,可穿戴式除颤器成为心律失常领域的一大研究热点。有心脏性猝死风险的人无需手术,只要穿戴上这种除颤器就可监测室性心律失常,一旦识别到恶性心律失常发生,除颤器就会报警并提醒即将放电,从而挽救患者的生命。

JACC:雷诺嗪对高风险心脏复律除颤器植入患者的预后影响

对于心脏复律除颤器(ICDs)植入患者,室性心动过速(VT)和室颤(VF)一直是比较棘手的问题。本研究的目的旨在评估雷诺嗪是否能降低ICD患者的VT、VF和死亡的发生风险。本研究是随机双盲对照研究,将高风险的ICD患者随机分成1000mg雷诺嗪一天两次治疗组和安慰剂组,主要终点事件是需要ICD治疗的室性心动过速或室颤甚至死亡。最终共纳入了1012例ICD患者(510例纳入雷诺嗪治疗组,502例纳入

Baidu
map
Baidu
map
Baidu
map